PRAX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
106.9M
+10.3%
96.9M
-8.5%
105.9M
+9.1%
97.0M
+23.8%
78.4M
R&D
64.2M
-7.5%
69.4M
-11.0%
78.0M
+0.6%
77.5M
+17.8%
65.8M
SG&A
42.7M
+55.4%
27.5M
-1.4%
27.9M
+42.7%
19.5M
+55.5%
12.6M
Operating Income
-106914000
-10.3%
-96904000
+8.5%
-105860000
-9.1%
-97044000
-23.8%
-78359000
EBITDA
-106881000
-10.3%
-96871000
+8.5%
-105821000
-9.1%
-97016000
-23.8%
-78340000
Net Income
-94234000
-12.6%
-83720000
+9.6%
-92561000
-4.1%
-88911000
-20.3%
-73934000
EPS (Basic)
$-3.23
-12.5%
$-2.87
+10.3%
$-3.20
+8.3%
$-3.49
-3.9%
$-3.36
EPS (Diluted)
$-3.23
-12.5%
$-2.87
+10.3%
$-3.20
+8.3%
$-3.49
-3.9%
$-3.36
Shares (Diluted)
29.2M
+0.2%
29.1M
+0.9%
28.9M
+13.2%
25.5M
+16.1%
22.0M
Praxis Precision Medicines (PRAX) — Financials